Clinical trial

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT03761225

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-09-01

PhasePHASE3

Study timeline

Study start (actual)2014-09-01Date precision: month

Registry last updated2023-09-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castrate Resistant Prostate Cancerunresolved

Interventions

MasitinibDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

PrednisoneDRUG · verified · RxNorm: prednisone

PlaceboDRUG

Sponsors & collaborators

AB Sciencelead sponsor

Mapped research locations

MilanItaly1 Saint PetersburgRussia1 PisaItaly1 Kuala LumpurMalaysia1 NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03761225 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.